SMS Pharmaceuticals Ltd — Capital/Financing Update 2025

May 30, 2025

==> picture [241 x 158] intentionally omitted <==

Date: 30[th] May, 2025 To, The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

Security Code: 532815

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Symbol: SMSPHARMA

Dear Sir/Madam,

Subject: Statement of deviation or variation in utilisation of funds raised through Preferential Issue for the quarter ended March 31, 2025

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI circular no. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended on March 31, 2025, there was no deviation or variation in the utilisation of proceeds of issuance of Convertible Warrants from the objects stated in the notice dated February 08, 2024 calling Extraordinary General Meeting on March 06, 2024.

The Company has allotted 90,00 000 warrants on receipt of 25% upfront amount March 19, 2024, out of which 40,00,000 has been converted in equity shares on March 27, 2025, upon receipt of balance 75% amount from the 2 allottees.

Please find enclosed herewith the statement of deviation or variation in utilisation of funds raised through preferential issue for the quarter ended March 31, 2025.

We request to kindly take note of the same

Thanking you

Yours faithfully

For SMS Pharmaceuticals Limited

THIRUMALE Digitally signed by THIRUMALESH TUMMA SH TUMMA Date: 2025.05.30 18:33:55 +05'30'

Thirumalesh Tumma Company Secretary